UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

Journal of clinical oncology, 2010-03, Vol.28 (9), p.1547-1553

2010

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective

Future oncology (London, England), 2022-04, Vol.18 (11), p.1313-1320

2022

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

The New England journal of medicine, 2009-04, Vol.360 (14), p.1408-1417

2009

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Journal of hepatology, 2018-08, Vol.69 (2), p.353-358

2018

Link zum Volltext

Verfügbarkeit prüfen

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

Cancer and metastasis reviews, 2020-12, Vol.39 (4), p.1143-1157

2020

Link zum Volltext

Verfügbarkeit prüfen

Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.412-412

2018

Link zum Volltext

Verfügbarkeit prüfen

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

ESMO open, 2020-05, Vol.5 (3), p.e000662-e000662, Article e000662

2020

Link zum Volltext

Verfügbarkeit prüfen

Cancer epidemiology in Central, South and Eastern European countries

Croatian medical journal, 2011-08, Vol.52 (4), p.478-487

2011

Link zum Volltext

Verfügbarkeit prüfen

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2215-2222

2017

Link zum Volltext

Verfügbarkeit prüfen

Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.668-668

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Journal of clinical oncology, 2010-01, Vol.28 (3), p.466-474

2010

Link zum Volltext

Verfügbarkeit prüfen

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4544-4550

2008

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

Journal of clinical oncology, 2011-05, Vol.29 (15), p.1997-2003

2011

Link zum Volltext

Verfügbarkeit prüfen

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Journal of clinical oncology, 2012-10, Vol.30 (29), p.3588-3595

2012

Link zum Volltext

Verfügbarkeit prüfen

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology oncology research, 2020-10, Vol.26 (4), p.2201-2207

2020

Link zum Volltext

Verfügbarkeit prüfen

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

European journal of cancer (1990), 2017-06, Vol.78, p.61-69

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(107)

Publikationsform

Artikel
(127)
Webseiten
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(62)
Life Sciences & Biomedicine
(61)
Science & Technology
(61)
Male
(49)
Oncology
(49)
Female
(47)
Middle Aged
(43)
Aged
(42)
Adult
(36)
Treatment Outcome
(29)
Aged, 80 And Over
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Disease-Free Survival
(17)
Tumors
(16)
Biological And Medical Sciences
(15)
Fluorouracil - Administration & Dosage
(15)
Antineoplastic Agents - Therapeutic Use
(14)
Cancer Research
(14)
Chemotherapy
(13)
Metastasis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib

Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

Cancer epidemiology in Central, South and Eastern European countries

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma

Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

Suchergebnisse filtern